Table 3 Prognostic value of preoperative Cyfra21-1 and SCC-Ag level in ESCC patients
Biomarker | Cyfra21-1 | SCC-Ag | ||||||
|---|---|---|---|---|---|---|---|---|
Level | No. | Median OS | 5-year survival | P value* | No. | Median OS | 5-year survival | P value* |
Total | Â | Â | Â | <0.001 | Â | Â | Â | <0.001 |
 Low | 198 | 91.9 | 85% |  | 103 | 89.7 | 82% |  |
 High | 181 | 46.6 | 33% |  | 276 | 63.7 | 53% |  |
pTNM stage | Â | Â | Â | Â | Â | Â | Â | Â |
 Stage IIA |  |  |  | <0.001 |  |  |  | 0.069 |
  Low | 75 | 102.6 | 93% |  | 46 | 85.7 | 86% |  |
  High | 52 | 59.9 | 54% |  | 81 | 78.2 | 72% |  |
Stage IIB | Â | Â | Â | <0.001 | Â | Â | Â | <0.001 |
  Low | 123 | 84.4 | 80% |  | 57 | 73.7 | 78% |  |
  High | 129 | 41.1 | 25% |  | 195 | 57.1 | 45% |  |